Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY

Innoviva, Inc.

2023-FY EPS reported $2.20 revenue$310,463,000

Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.
Q4 GSK royalty revenue $69.6M; net product sales $19.7M (+35% YoY) driven by GIAPREZA ($13.1M) and XERAVA ($5.2M).
Repurchased 1.1M shares for $15.4M in Q4; full-year repurchases $76.5M; $15M authorization remaining.
XACDURO approved for HABP/VABP; zoliflodacin met Phase 3 primary endpoint; NDA filing within 12 months.
Cash and receivables >$275M; strategic assets valued at $561M; invested $5M in Gate Neurosciences.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Innoviva, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net income was $61.5 million, or $0.97 basic per share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: net income was $61.5 million, or $0.97 basic per share
Result: reported results

Exact text from the filing

On February 29, 2024, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-029378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.